Biological variation of plasma and urinary markers of acute kidney injury in patients with chronic kidney disease

Clinical Chemistry

Volumn 62, Issue 6, 2016, Pages 876-883

  Carter, Joanne L ^a   Parker, Christopher T ^a   Stevens, Paul E ^b   Eaglestone, Gillian ^b   Knight, Sarah ^b   Farmer, Christopher K T ^b   Lamb, Edmund J ^a,b  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLGLUCOSAMINIDASE; ALBUMIN; ALPHA 1 MICROGLOBULIN; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETES MELLITUS; FEMALE; GENETIC VARIATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; REFERENCE VALUE; URINALYSIS; BLOOD; CHRONIC KIDNEY FAILURE; KIDNEY FUNCTION TEST; MIDDLE AGED; URINE; VERY ELDERLY;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CREATININE; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84971350734     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.250993     Document Type: Article

References (37)

1. Lewington AJ, Sayed A. Acute kidney injury: how do we define it? Ann Clin Biochem 2010;47:4-7.
2. Stevens PE, Tamimi NA, Al-Hasani MK, Mikhail AI, Kearney E, Lapworth R, et al. Non-specialist management of acute renal failure. QJM 2001;94:533-40.
3. Kidney Disease Improving Global Outcomes. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int 2012;2(Suppl):1-138.
4. Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant 2009;24:3263-5.
5. American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005;16:1886-903.
6. Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 2007;11:R127.
7. Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 2014;51:335-51.
8. Bonventre JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant 2009;24:3265-8.
9. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005;16:3046-52.
10. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013;17:R25.
11. Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992;38(Suppl 1):S14-9.
12. Payn MM, Webb MC, Lawrence D, Lamb EJ. Alpha1-microglobulin is stable in human urine ex vivo. Clin Chem 2002;48:1136-8.
13. Weber MH, Verwiebe R. Alpha 1-microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction. Eur J Clin Chem Clin Biochem 1992;30:683-91.
14. Yamashita T, Doi K, Hamasaki Y, Matsubara T, Ishii T, Yahagi N, et al. Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study. Crit Care 2014;18:716.
15. Devarajan P, Krawczeski CD, Nguyen MT, Kathman T, Wang Z, Parikh CR. Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am J Kidney Dis 2010;56:632-42.
16. Parikh CR, Garg AX. Testing new biomarkers for acute kidney injury: association, prediction, and intervention. Am J Kidney Dis 2009;54:987-9.
17. Soto K, Papoila AL, Coelho S, Bennett M, Ma Q, Rodrigues B, et al. Plasma NGAL for the diagnosis of AKI in patients admitted from theemergency department setting. Clin J Am Soc Nephrol 2013;8:2053-63.
18. Ricos C, Iglesias N, Garcia-Lario JV, Simon M, Cava F, Hernandez A, et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007;44:343-52.
19. Houillier P, Coste J, Froissart M. How many measurements to make a decision? Clin J Am Soc Nephrol 2010; 5:1161-2.
20. Fraser CG, Harris EK. Generation and applicationofdata on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
21. Fraser CG, Hyltoft Petersen P, Libeer JC, Ricos C. Proposals for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 1997;34:8-12.
22. Bartlett WA, Braga F, Carobene A, Coskun A, Prusa R, Fernandez-Calle P, et al. A checklist for critical appraisal of studies of biological variation. Clin Chem Lab Med 2015;53:879-85.
23. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008;3:665-73.
24. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
25. Fokkema MR, Herrmann Z, Muskiet FA, Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006;52:1602-3.
26. Simundic AM, Kackov S, Miler M, Fraser CG, Petersen PH. Terms and symbols used in studies on biological variation: the need for harmonization. Clin Chem 2015;61:438-9.
27. Roraas T, Petersen PH, Sandberg S. Confidence intervals and power calculations for within-person biological variation: effect ofanalytical imprecision, number of replicates, number of samples, and number of individuals. Clin Chem 2012;58:1306-13.
28. Kidney Disease Improving Global Outcomes. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2013; 3:1-150.
29. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-8.
30. Krawczeski CD, Goldstein SL, Woo JG, Wang Y, Piyaphanee N, Ma Q, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol 2011;58:2301-9.
31. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16:3365-70.
32. Basu RK, Wong HR, Krawczeski CD, Wheeler DS, Manning PB, Chawla LS, et al. Combining functional and tubular damage biomarkersimproves diagnostic precision for acute kidney injury after cardiac surgery. J Am Coll Cardiol 2014;64:2753-62.
33. Koyner JL, Garg AX, Coca SG, Sint K, Thiessen-Philbrook H, Patel UD, et al. Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol 2012;23:905-14.
34. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis 2013;62:1095-101.
35. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerularfiltration rate. KidneyInt 2010;78:486-94.
36. Nejat M, Hill JV, Pickering JW, Edelstein CL, Devarajan P, Endre ZH. Albuminuria increases cystatin C excretion: implications for urinary biomarkers. Nephrol Dial Transplant 2011;27(Suppl 3):iii, 96-103.
37. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. JAm Soc Nephrol 2004;15: 1677-89.